Works by Fukuhara, Tatsuro


Results: 22
    1
    2

    Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43630-3
    By:
    • Nomura, Miyuki;
    • Ohuchi, Mai;
    • Sakamoto, Yoshimi;
    • Kudo, Kei;
    • Yaku, Keisuke;
    • Soga, Tomoyoshi;
    • Sugiura, Yuki;
    • Morita, Mami;
    • Hayashi, Kayoko;
    • Miyahara, Shuko;
    • Sato, Taku;
    • Yamashita, Yoji;
    • Ito, Shigemi;
    • Kikuchi, Naohiko;
    • Sato, Ikuro;
    • Saito, Rintaro;
    • Yaegashi, Nobuo;
    • Fukuhara, Tatsuro;
    • Yamada, Hidekazu;
    • Shima, Hiroshi
    Publication type:
    Article
    3

    First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 4, p. 452, doi. 10.1093/jjco/hyad195
    By:
    • Imai, Hisao;
    • Kijima, Takashi;
    • Azuma, Koichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Yamaguchi, Teppei;
    • Tanizaki, Junko;
    • Yoneshima, Yasuto;
    • Fujita, Kohei;
    • Watanabe, Satoshi;
    • Kitazono, Satoru;
    • Fukuhara, Tatsuro;
    • Hataji, Osamu;
    • Toi, Yukihiro;
    • Mizutani, Hideaki;
    • Hamakawa, Yusuke;
    • Maemondo, Makoto;
    • Ohsugi, Tomoyuki;
    • Suzuki, Keisuke;
    • Horinouchi, Hidehito
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10

    First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.

    Published in:
    International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1354, doi. 10.1007/s10147-023-02390-2
    By:
    • Nishio, Makoto;
    • Ohe, Yuichiro;
    • Ikeda, Satoshi;
    • Yokoyama, Toshihide;
    • Hayashi, Hidetoshi;
    • Fukuhara, Tatsuro;
    • Sato, Yuki;
    • Tanaka, Hiroshi;
    • Hotta, Katsuyuki;
    • Sugawara, Shunichi;
    • Daga, Haruko;
    • Okamoto, Isamu;
    • Kasahara, Kazuo;
    • Naito, Tateaki;
    • Li, Li;
    • Gupta, Ravi G.;
    • Bushong, Judith;
    • Mizutani, Hideaki
    Publication type:
    Article
    11

    Phase II study of carboplatin–paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 4, p. 676, doi. 10.1007/s10147-021-02113-5
    By:
    • Oizumi, Satoshi;
    • Takamura, Kei;
    • Harada, Toshiyuki;
    • Tachihara, Motoko;
    • Morikawa, Naoto;
    • Honda, Ryoichi;
    • Watanabe, Satoshi;
    • Asao, Tetsuhiko;
    • Kunisaki, Mamoru;
    • Fukuhara, Tatsuro;
    • Noro, Rintaro;
    • Kikuchi, Eiki;
    • Tsutani, Yasuhiro;
    • Tenma, Toshiyuki;
    • Kobayashi, Kunihiko;
    • Dosaka-Akita, Hirotoshi
    Publication type:
    Article
    12
    13

    Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

    Published in:
    Thoracic Cancer, 2021, v. 12, n. 14, p. 2113, doi. 10.1111/1759-7714.14048
    By:
    • Hisashi Tanaka;
    • Yukihiro Hasegawa;
    • Yuka Fujita;
    • Atsushi Nakamura;
    • Eiki Kikuchi;
    • Yasutaka Kawai;
    • Toshiyuki Harada;
    • Naomi Watanabe;
    • Hiroshi Yokouchi;
    • Kazuhiro Usui;
    • Ryota Saito;
    • Hiroshi Watanabe;
    • Tomomi Masuda;
    • Tatsuro Fukuhara;
    • Keita Kudo;
    • Ryoichi Honda;
    • Satoshi Oizimi;
    • Makoto Maemondo;
    • Akira Inoue;
    • Naoto Morikawa
    Publication type:
    Article
    14

    Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407.

    Published in:
    Cancer Science, 2023, v. 114, n. 8, p. 3330, doi. 10.1111/cas.15816
    By:
    • Sugawara, Shunichi;
    • Tanaka, Kentaro;
    • Imamura, Fumio;
    • Yamamoto, Nobuyuki;
    • Nishio, Makoto;
    • Okishio, Kyoichi;
    • Hirashima, Tomonori;
    • Tanaka, Hiroshi;
    • Fukuhara, Tatsuro;
    • Nakahara, Yasuharu;
    • Kurata, Takayasu;
    • Katakami, Nobuyuki;
    • Okada, Morihito;
    • Horinouchi, Hidehito;
    • Udagawa, Hibiki;
    • Kasahara, Kazuo;
    • Satouchi, Miyako;
    • Saka, Hideo;
    • Tokito, Takaaki;
    • Hosomi, Yukio
    Publication type:
    Article
    15

    First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset*.

    Published in:
    Cancer Science, 2021, v. 112, n. 12, p. 5000, doi. 10.1111/cas.15144
    By:
    • Satouchi, Miyako;
    • Nosaki, Kaname;
    • Takahashi, Toshiaki;
    • Nakagawa, Kazuhiko;
    • Aoe, Keisuke;
    • Kurata, Takayasu;
    • Sekine, Akimasa;
    • Horiike, Atsushi;
    • Fukuhara, Tatsuro;
    • Sugawara, Shunichi;
    • Umemura, Shigeki;
    • Saka, Hideo;
    • Okamoto, Isamu;
    • Yamamoto, Nobuyuki;
    • Sakai, Hiroshi;
    • Kishi, Kazuma;
    • Katakami, Nobuyuki;
    • Horinouchi, Hidehito;
    • Hida, Toyoaki;
    • Okamoto, Hiroaki
    Publication type:
    Article
    16
    17

    First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset.

    Published in:
    Cancer Science, 2020, v. 111, n. 12, p. 4480, doi. 10.1111/cas.14647
    By:
    • Satouchi, Miyako;
    • Nosaki, Kaname;
    • Takahashi, Toshiaki;
    • Nakagawa, Kazuhiko;
    • Aoe, Keisuke;
    • Kurata, Takayasu;
    • Sekine, Akimasa;
    • Horiike, Atsushi;
    • Fukuhara, Tatsuro;
    • Sugawara, Shunichi;
    • Umemura, Shigeki;
    • Saka, Hideo;
    • Okamoto, Isamu;
    • Yamamoto, Nobuyuki;
    • Sakai, Hiroshi;
    • Kishi, Kazuma;
    • Katakami, Nobuyuki;
    • Horinouchi, Hidehito;
    • Hida, Toyoaki;
    • Okamoto, Hiroaki
    Publication type:
    Article
    18

    KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer.

    Published in:
    Cancer Science, 2019, v. 110, n. 3, p. 1012, doi. 10.1111/cas.13932
    By:
    • Nishio, Makoto;
    • Takahashi, Toshiaki;
    • Yoshioka, Hiroshige;
    • Nakagawa, Kazuhiko;
    • Fukuhara, Tatsuro;
    • Yamada, Kazuhiko;
    • Ichiki, Masao;
    • Tanaka, Hiroshi;
    • Seto, Takashi;
    • Sakai, Hiroshi;
    • Kasahara, Kazuo;
    • Satouchi, Miyako;
    • Han, Shi Rong;
    • Noguchi, Kazuo;
    • Shimamoto, Takashi;
    • Kato, Terufumi
    Publication type:
    Article
    19

    Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing.

    Published in:
    Cancer Science, 2018, v. 109, n. 12, p. 3921, doi. 10.1111/cas.13820
    By:
    • Iwama, Eiji;
    • Sakai, Kazuko;
    • Azuma, Koichi;
    • Harada, Daijiro;
    • Nosaki, Kaname;
    • Hotta, Katsuyuki;
    • Nishio, Makoto;
    • Kurata, Takayasu;
    • Fukuhara, Tatsuro;
    • Akamatsu, Hiroaki;
    • Goto, Koichi;
    • Shimose, Takayuki;
    • Kishimoto, Junji;
    • Nakanishi, Yoichi;
    • Nishio, Kazuto;
    • Okamoto, Isamu
    Publication type:
    Article
    20
    21
    22